US and Europe biosimilars, clinical trials in EU & US

Biosimilars: US and Europe

COVID-19 and its economic impacts have only strengthened the case for further developing a sustainable global biosimilars market. In this Insights@CromosPharma paper we explore the development of the European biosimilar market and contrast this with the US. We also look at the key challenges and opportunities facing biosimilar developers.



To arrange an introductory meeting and find out how our experience can benefit your next clinical project.